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Abstract
X-linked Glucose-6-phosphate dehydrogenase (G6PD) A- deficiency is prevalent in sub-
Saharan Africa populations, and has been associated with protection from severe malaria.
Whether females and/or males are protected by G6PD deficiency is uncertain, due in part to
G6PD and malaria phenotypic complexity and misclassification. Almost all large association
studies have genotyped a limited number ofG6PD SNPs (e.g. G6PD202 / G6PD376), and
this approach has been too blunt to capture the complete epidemiological picture. Here we
have identified 68 G6PD polymorphisms and analysed 29 of these (i.e. those with a minor
allele frequency greater than 1%) in 983 severe malaria cases and controls in Tanzania.
We establish, across a number of SNPs including G6PD376, that only female heterozy-
gotes are protected from severe malaria. Haplotype analysis reveals the G6PD locus to be
under balancing selection, suggesting a mechanism of protection relying on alleles at mod-
est frequency and avoiding fixation, where protection provided by G6PD deficiency against
severe malaria is offset by increased risk of life-threatening complications. Our study also
demonstrates that the much-needed large-scale studies of severe malaria and G6PD enzy-
matic function across African populations require the identification and analysis of the full
repertoire of G6PD genetic markers.
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Author Summary
Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme that protects red
blood cells from oxidative damage. Numerous genetic variants of G6PD, residing in the X
chromosome, are found among African populations: mutations causing A- deficiency can
lead to serious clinical outcomes (including hemolytic anemia) but also confer protection
against severe malaria. Epidemiological studies have used some of the genetic markers that
cause A- deficiency to establish who is protected from severe malaria, with differing re-
sults. Whether females, with one or two copies of mutant genes, males with one copy, or
both genders are protected is uncertain. This uncertainty is due to G6PD and malaria phe-
notypic complexity and misclassification, and to genetic differences between populations
and the limited numbers of genetic markers (usually 2) considered. In this study we ana-
lysed more than 30 G6PD genetic markers in 506 Tanzanian children with severe malaria
and 477 without malaria. We found that only females with one normal and one mutant
copy of the gene (heterozygotes) were protected from severe malaria. Further, we estab-
lished that the G6PD gene is under evolutionary pressure with the likely mechanism being
selection by malaria. Our work demonstrates that studies of severe malaria and G6PD en-
zymatic function across African populations require, in addition to complete and accurate
G6PD phenotypic classification, the identification and analysis of the full repertoire of
G6PD genetic markers.
Introduction
Amongst the approximately 190 genetic variants causing clinical deficiency of Glucose-6-phos-
phate dehydrogenase (G6PD) that have been characterised [1], the A- deficiency is the most
common in sub-Saharan Africa populations, and is associated with protection from severe ma-
laria [2,3]. An understanding of how this protection works may assist with the design of anti-
malarial vaccines and drugs. Establishing whether malaria patients are G6PD deficient is also
important because of the potential use of 8-aminoquinoline drugs (e g, primaquine and its de-
rivatives) for malaria elimination in sub-Saharan Africa [4]. Primaquine is active against all
liver stages of Plasmodium, and also offers activity against P. falciparum gametocytes, thereby
blocking transmission to mosquitoes [4]. However, primaquine is haemotoxic, and can cause
haemolytic anaemia in G6PD-deficient individuals. G6PD status can be quantified using enzy-
matic activity assays and is required for unambiguous identification of G6PD-deficiency, espe-
cially in mosaic female heterozygotes due to the X-linkage of the trait [5]. Cytochemical
methods have been suggested as an alternative [5], but are not efficient for large studies, and
genotyping has been used as a high throughput approach. Whilst genotyping approaches have
been advocated, there is evidence of extensive diversity at the G6PD locus (X chromosome,
16.2kb), with more than 150 single nucleotide polymorphisms (SNPs) reported [1]. Many of
these known genetic variants result in amino acid changes and have been detected through se-
quencing the G6PD gene locus in enzyme deficient individuals. The G6PD and the Inhibitor of
kappa light polypeptide gene (IKBKG, involved in immunity, inflammation and cell survival
pathways [6], and with mutations linked to Incontinentia Pigmenti [7]) loci overlap each
other, including a shared conserved promoter region that has bidirectional housekeeping activ-
ity [7]. The region containing the G6PD gene and the 5-prime end of the IKBKG gene contains
Alu elements [7]. The genetic variability in G6PD and IKBKG is complex [7], and new alleles
are still being discovered, making a simple G6PD genetic approach unreliable [8,9].
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Despite these limitations, genotyping of the 202A/376G G6PD A-allele (with*12% of nor-
mal enzymatic activity [10]) has been used extensively in epidemiological studies to investigate
protection against severe malaria [8, 10–19]. It has been shown that coexistence of the two mu-
tations is responsible for enzyme deficiency in G6PD A- because they act synergistically in
causing instability of the enzyme [20]. They also lead to structural changes in the enzyme pro-
tein. However, even in large well-powered studies, associations between 202A/376G G6PD and
protection from severe disease have been inconsistent, revealing protective effects in female
heterozygotes [8, 11,17,18,19], in male hemizygotes [12,13], in both [14], or no protection [15].
These phenotype-genotype inconsistencies may be explained in part by variation in study de-
sign, G6PD and malaria phenotypic complexity and misclassification and incomplete experi-
mental data [8]. However, it has been recognised that allelic heterogeneity, specifically other
unknown polymorphisms, has a role [3,5,8], with evidence from studies in West Africa [5,8]
for A- deficiency and in Southeast Asia and Oceania for other deficiency types [3]. In particu-
lar, in the West African setting, the frequency of the 202A allele is often substantially lower
than rates of enzyme deficiency indicating a role for other alleles; inclusion of other G6PD
polymorphisms (Santamaria 542T/376G—*2% residual enzymatic activity, Betica-Selma
968C/376G—*11% activity)[10, 16] was required to capture an association between G6PD
deficiency and severe malaria in The Gambia [8].
Further understanding is required of the true extent of genetic diversity within the G6PD
locus, how this relates to enzyme function, and how it varies between regions and ethnic
groups, if genetic epidemiological studies are to provide robust and reproducible findings. A re-
cent study in Mali using 58 SNPs across the G6PD gene found differences in core haplotypes
and their frequencies between Dogon and Fulani ethnic groups [9]. The latter group is known
to have substantially reduced susceptibility to malaria when compared to sympatric popula-
tions [9]. Whilst some ethnicity specific SNP associations were observed with mild malaria, the
prevalence of severe malaria was too low for any robust associations to be detected.
Here we investigate associations between 68 SNPs within the G6PD and surrounding loci
(IKBKG and CTAG1A/B), including the 202, 376, 542, 680 and 968 A- deficiency polymor-
phisms (referred to here as G6PD202, G6PD376, and so forth), and severe malaria. The work is
set within a case-control study (n = 983; 506 cases and 477 controls) conducted in an area of in-
tense malaria transmission in the Tanga region in northeastern Tanzania [17]. To complement
the case-control collection, we genotyped samples from 60 healthy parental and child trios
(120 parents, 60 children), collected in the same geographical region. We find very strong asso-
ciations between multiple SNPs across the G6PD gene and protection from severe malaria in
female heterozygotes but not in hemizygous males. Very high linkage disequilibrium across
this locus allowed us to distil this SNP diversity into just 4 G6PD alleles, ranging in frequency
from*6% to>60%, and 8 common genotypes (>1%), 2 of which are associated with protec-
tion from severe malaria.
In summary, this study identifies specific G6PD alleles that confer resistance to severe ma-
laria in this population and reveals a potentially important role of female heterozygotes in
maintaining the high frequency of G6PD polymorphisms in malaria endemic populations.
Results
Of the severe malaria cases (n = 506), many had severe malarial anaemia (48.6%) or acidosis
(57.5%) phenotypes (Table 1). Compared to controls (n = 477), malaria cases tended to be
younger and male, and with more individuals outside the 7 main ethnic groups (P<0.05). Ma-
laria cases were less likely to be of blood group O (O vs. A/B/AB, OR 0.726, 95% CI 0.534,
0.986; P = 0.04), with alpha thalassaemia of α-/α- (α-/α- vs. αα/αα or αα/α-, Odds Ratio (OR)
African G6PD Alleles and Severe Malaria in Tanzania
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0.639, 95% CI 0.401–1.018, P = 0.06) or present with the sickle cell protective AS genotype (AS
vs. other, OR 0.053, 95% CI 0.021–0.132). The sickle cell AS genotype frequency in parents
(6.3%) and children (5.4%) in the trio validation study lay between the estimates for the cases
(1.0%) and controls (16.5%). As expected, the G6PD542, 680 and 968 polymorphisms found in
Table 1. Baseline and clinical characteristics.
Controls (n = 477) Cases (n = 506) Difference P-value
Age* (median, range) (2.9) (0.9–10.9) (1.7) (0.2–10.0) <0.0001
Gender—Female 255 53.5% 236 46.6% 0.04
Ethnicity 0.0005
Mzigua 158 33.1% 149 29.4%
Wasambaa 130 27.3% 130 25.7%
Wabondei 78 16.4% 79 15.6%
Chagga 50 10.5% 47 9.3%
Mmbena 23 4.8% 25 4.9%
Other 5 1.0% 39 7.7%
Mngoni 18 3.8% 19 3.8%
Pare 15 3.1% 18 3.6%
Blood group 0.22
A 115 24.4% 145 29.8%
AB 20 4.2% 18 3.7%
B 100 21.2% 107 22.0%
O 236 50.1% 216 44.4%
Sickle HbS (rs334)** <0.0001
AA 385 83.5% 473 97.9%
AS 76 16.5% 5 1.0%
SS 0 0.0% 5 1.0%
Alpha thalassaemia 0.15
αα/αα 224 47.2% 236 51.9%
αα/α- 199 41.9% 184 40.4%
α-/α- 52 10.9% 35 7.7%
G6PD202A 92 20.0% 79 16.3% 0.02
G6PD376G 178 38.5% 173 37.4% 0.007
G6PD542T 477 0% 506 0% -
G6PD680T 477 0% 506 0% -
G6PD968C 477 0% 506 0% -
Clinical phenotype NA
Any severe malaria - - 506 100%
Any SMA*** - - 246 48.6%
Any CM - - 99 19.6%
Both SMA+CM - - 41 8.1%
Any RD - - 146 28.9%
Acidosis**** - - 291 57.5%
* in months, SMA: severe malarial anaemia, CM: cerebral malaria, RD: respiratory distress
**Absence of HbC and HbE mutations
*** hb<5gdl
**** Blood lactate>5mmol/l.
doi:10.1371/journal.pgen.1004960.t001
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West African populations [8,9] were all monomorphic in both cases and controls, as well as in
the 60 parental-child trios, and were therefore excluded from further analysis.
The G6PD202A and G6PD376G A- alleles were among the 29 SNPs retained with minor al-
lele frequency (MAF) in excess of 1% (S2 Table). Both G6PD202A (case 16.3% vs. control
20.0%) and G6PD376G (37.4% vs. 38.5%) allele frequencies were lower in malaria cases than in
controls (P<0.02) (Table 1), and broadly similar to the trio study parents (202A 16.8%, 376G
31.3%) and children (202A 15.0%, 376G 24.1%) (S3 Table). A SNP-by-SNP association analysis
revealed 11 multiple loci where female heterozygotes appeared to be protected from severe
malaria in all its clinical phenotypes (Table 2, Fig. 1, S1 Fig.) except for cerebral malaria where
although there was evidence of heterozygous advantage effects (OR* 0.5), they were non-sig-
nificant due to the small number of cases (99) (P>0.018). The G6PD376 and rs762515 poly-
morphisms (both flanking G6PD202) were the only SNPs associated with all non-cerebral
malaria clinical phenotypes. The association hits across clinical phenotypes included a “core”
region consisting of 7 SNPs (rs5986990, rs2515905, rs2515904, G6PD376, G6PD202, rs762515,
rs762516) in perfect linkage disequilibrium (D’ = 1), where female heterozygotes were 48.2%
and 72.4% less likely to be a severe malaria case (any definition) than female homozygote geno-
types (P<0.006, Table 2). By comparison, there were no significant associations between G6PD
genotype and severe malaria in hemizygous males (P>0.310).
The correlation between the 29 SNPs was high (linkage disequilibrium D’median (IQR): all
subjects 0.987 (0.811–0.997); female controls 0.988 (0.731–0.998)). Similarly, LD was high across
this region in the trio parents (all: 0.998 (0.995–0.999); female only: 0.998 (0.995–0.999)) and
children (0.998 (0.996–0.999)) (S2 Fig.). This high LD allowed us to define a small number of
haplotypes/G6PD alleles (4) that accounted for 99.6% of all alleles typed for the “core” region
(haplotype 1 = GGGAGTC, 2 = AACGGCT (6 mutations), 3 = AACGACT (7 mutations),
4 = AGGGGCC (3 mutations)). Female controls had a higher frequency of the three haplotypes
(2–4) containing mutations. Whilst protective effects were observed in females (and not males)
for these three haplotypes (OR 0.683–0.783) compared to the common type (haplotype 1, fre-
quency*60%), they were not statistically significant (P>0.186), due to the heterozygous nature
of the protection in females (S4 Table). Further analysis accounting for the genotypic combina-
tions of G6PD alleles confirmed that a combination of haplotypes 1 and either 2 or 3 were pro-
tective (OR<0.38, P<0.006) compared to a double haplotype 1 (wild-type) genotype (Table 3).
This result shows that haplotypes with the 376Gmutation have similar protective effect in het-
erozygotes irrespective of the presence or absence of the 202Amutation, indicating that the
376Gmutation is causal. The genotypic combination of haplotypes 1 and 4 also had a potentially
protective effect (OR = 0.599), but it failed to reach statistical significance (P = 0.11).
It is possible that the greater protective effects of haplotypes 2 and 3, could be due to the
presence of more mutations (6), leading to a possible compound heterozygous advantage ef-
fect. The number of heterozygous genotype calls in female controls was greater than in cases
(case vs. control median / mean: All SNPs 10 / 9.1 vs. 7 / 7.6, P<0.001; 7 core SNPs, 3 / 3.2 vs.
0 / 2.1, P<0.0001). The Tajima’s Dmetric was applied to assess if the excess number of hetero-
zygous alleles led to evidence of balancing selection in the G6PD gene. There was very strong
evidence of balancing selection across all groups (Tajima’s D> 2.6, female controls 2.9). The
magnitude of effect is at the extreme positive tail of an observed negatively centred African
population distribution [21], where predominantly negative values demonstrate either slow
growth from a small population size, or a bottleneck that is much older than that of non-Afri-
cans [21]. This result implies that the (high) allele frequency of the SNPs in the G6PD gene is
maintained mainly, and perhaps entirely, by the protection against severe malaria of heterozy-
gous females through a balancing selection mechanism. This selection mechanism is also pre-
dicted by population genetic theory [22], and consistent with empirical data from other studies
African G6PD Alleles and Severe Malaria in Tanzania
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[8,18]. Such mechanisms exist at other malaria candidate loci in the autosomal regions, for ex-
ample at the HbAS sickle trait [23]. There was no evidence of epistatic effects between HbS and
G6PD on severe malaria in females (P = 0.34), nor males (P = 0.98). Similarly, no evidence of
epistasis between alpha thalassaemia and G6PD (female P = 0.44; male P = 0.21).
Fig 1. Severemalaria association results* (males—solid, females—hollow circles). *Minimum p-values from single SNP analysis adjusted for age and
ethnicity. The dashed line represents a p-value cut-off of 0.006; the vertical dashed line represents a p-value cut-off of 0.006; theG6PD/IKBKG region is
bolded on the right, and the 5 remaining SNPs are in the CTAG1A/B region.
doi:10.1371/journal.pgen.1004960.g001
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Discussion
Although G6PD A- deficiency is known to protect against severe malaria in African popula-
tions, the underlying genetic mechanisms are not well understood. P. falciparum development
is hindered in G6PD deficient red cells [24], slowing the rate of parasite replication and reduc-
ing the likelihood of severe disease. Suggested mechanisms include more efficient clearance of
the infected erythrocytes [25], lower abundance of P. falciparum 6-phosphogluconolactonase
mRNA in parasites from G6PD-deficient children [26], and impaired parasite replication [27].
By using the largest set of G6PD (and surrounding loci) SNPs (n = 68) in a genetic association
study, within a Tanzanian case-control setting, we have established a set of new G6PD alleles
associated with protection. These SNPs need to be further investigated to assess their effect on
enzyme function in light of potential use of primaquine for malaria elimination. After valida-
tion, these SNPs may be used to identify G6PD-deficient individuals in studies of
primaquine efficacy.
Further, we have shown that the protective effect of G6PD deficiency is limited to female
heterozygotes. This is entirely consistent with heterozygote advantage and balancing selection,
relying on alleles at modest frequency and avoiding fixation, where protection provided by this
G6PD deficiency against severe malaria is offset by increased risk of life-threatening complica-
tions, such as neonatal jaundice and haemolytic crises. In female heterozygotes, random inacti-
vation of one of the two X chromosomes results in some cells with normal enzyme and others
with mutant enzyme [11, 28, 29], reducing the risk of both anaemia and severe malaria. We ex-
pect that the fitness of normal male hemizygotes is the same as that of normal female homozy-
gotes (since all red cells will contain fully functional enzyme), and population genetic theory
also suggests that the fitness of G6PD-deficient male hemizygotes is the same as that of G6PD-
deficient female homozygotes. Under these conditions, it is expected that the female heterozy-
gote must be the genotype with the highest fitness [22]. Two independent studies [8, 18] in two
different populations, nearly 40 years apart, are consistent in this regard, with G6PD deficiency
Table 3. Severe malaria and combinations of haplotypes. *
Haplotypes
**
G6PD type
***
Control (n =
255)%
Case (n =
236) %
Odds ratio
****
95%
LCL
95%
UCL
P-
value
1,1 B, B 32.2 44.1 1.000 - - -
1,2 A, B 8.6 3.8 0.228 0.088 0.595 0.0025
1,3 A-, B 25.9 15.7 0.376 0.215 0.657 0.0006
1,4 B, B 14.1 13.6 0.599 0.319 1.122 0.1095
2,2 A, A 0.4 0.8 1.066 0.077 14.789 0.9621
2,3 A-, A 1.6 2.5 1.351 0.297 6.156 0.6974
2,4 A, B 0.8 0.8 1.781 0.215 14.749 0.5926
3,3 A-, A- 3.5 5.1 1.173 0.429 3.207 0.7554
3,4 A-, B 3.1 2.5 0.515 0.150 1.763 0.2905
4,4 B, B 2.7 1.7 0.367 0.092 1.472 0.1574
other Mixed 7.1 9.3 0.995 0.454 2.183 0.9903
LCL: lower conﬁdence interval, UCL: upper conﬁdence interval
* Based on rs5986990, rs2515905, rs2515904, G6PD376, G6PD202, rs762515, rs762516
** Haplotype 1 = GGGAGTC, 2 = AACGGCT, 3 = AACGACT, 4 = AGGGGCC
*** Based on G6PD202 and G6PD376
**** Adjusted for age and ethnicity
The statistically signiﬁcant results are bolded.
doi:10.1371/journal.pgen.1004960.t003
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A− being a balanced polymorphism with heterozygote advantage. Similarly, as the G6PD defi-
ciency A− has been estimated to be at least 5000 years old [3], balancing selection would ac-
count for it not having gone to fixation [22]. Further, balancing selection has been observed in
autosomal malaria candidate regions like FREM3, the major histocompatibility complex, and
the sickle cell trait loci [23].
Hitherto, there has been much uncertainty about the relationship between G6PD status and
susceptibility to malaria, due in part to G6PD and malaria phenotypic complexity and misclas-
sification, and potentially also from the genetic complexity of the G6PD locus with the presence
of multiple functional SNPs, each of which may separately modify an individual’s enzyme sta-
tus and susceptibility to malaria. Until very recently, almost all-large association studies geno-
typed a limited number of G6PD SNPs (e.g. G6PD202 / G6PD376 for A- deficiency), and this
approach has been too blunt to capture the full picture. However, analysis of 58 G6PD SNPs
has demonstrated major G6PD haplotypic differences between sympatric ethnic groups in
Mali [9] and genotyping of the G6PD968 polymorphism in addition to 202/376 revealed a fe-
male protective in a Gambian population [8]. With hindsight, it is clear that genotyping of
G6PD968 in another study in the same population [14] would have prevented misclassification
of two-thirds of the G6PD-deficient samples and the erroneous reporting of a male hemizygous
protective effect. Other studies reporting male hemizygous protective effects may also be con-
founded by allelic heterogeneity, which could be avoided by more comprehensive genotyping
and by phenotypic testing for G6PD enzyme activity. A comprehensive study would include a
full genetic survey of the G6PD and surrounding regions, with multiple populations and ethnic
groups, leading to a more complete map of G6PD that would guide future evolutionary and
association studies.
A surprising association result is that the G6PD376 mutation is potentially more influential
than G6PD202 and haplotypes that contain the 376G with or without the 202A mutation ap-
pear to be similar in terms of protective effect on heterozygotes. The 202A mutation is thought
to have a more severe effect on enzyme function than the 376G mutation (*12% and*83%
of normal function, respectively [10, 30]) and coexistence of 202A/376G is responsible for
G6PD A- enzyme deficiency [20], but it is possible that more subtle changes in enzyme struc-
ture or function also affect the outcome of malaria infection. Fully understanding the role of
G6PD requires further correlation of enzymatic activity with full sequences of G6PD and sur-
rounding loci, set within large severe-malaria case and control studies. There have been no
such studies to date. A recent study of four G6PD deficiency polymorphisms (202, 376, 968, Ile-
sha) and associated enzymatic activities for 110 sequenced genes in African Americans [31]
but included only 54 heterozygous females. Enzymatic activity for G6PD376G (A+, n = 28),
376G/202A (A- deficiency, n = 23), 376G/968C (A-, n = 1), 376G/202A/968C (A-, n = 1) and
Ilesha (E156K, Nigeria, non A-, n = 1) alleles was estimated to be*83%,*53%*58%,
*11% and*75% of normal, respectively. These results are consistent with deficiency increas-
ing with additional A- related polymorphism, and by implication will change levels of protec-
tion or susceptibility to malaria. Another recent study [32] in 1,828 Kenyan children suggested
that G6PD202 was responsible for the majority of G6PD enzyme deficiency but that 376G in-
creases the risk of deficiency in 202AG heterozygotes. Neither study considered
malaria outcomes.
In summary, through a much better understanding of the true extent of genetic diversity
within and around the G6PD locus, we have identified alleles associated with protection from
severe malaria in Tanzania, driven by a balancing heterozygous advantage mechanism. Further
work should extend the mapping of diversity at this genomic region, and identify how the re-
sulting mutations relate to enzyme function, and how they vary between region and ethnic
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group. In doing so, genetic epidemiological studies are likely to provide robust and repeatable
data, which may be used to develop interventions, and improve malaria disease control.
Materials and Methods
Study participants
The study was conducted in the Teule district hospital and surrounding villages in Muheza dis-
trict, Tanga region. In this region, mortality in children under 5 years of age is 165 per 1000
(Tanzanian census 2002) and transmission of P. falciparummalaria is intense (50–700 infected
bites/person/year) and perennial, with two seasonal peaks [17]. The community prevalence of
P. falciparum parasites in children aged 2–5 years in the study area was recorded as 88.2% in
2002 [17].
Severe malaria cases (n = 506), aged six months to ten years, were recruited during a one-
year period between June 2006 and May 2007, with patent parasitaemia, and fulfilling any one
of the following eligibility criteria; history of 2 or more convulsions in last 24 hours, prostration
(unable to sit unsupported if<9 months of age or drink at any age), reduced consciousness
(Blantyre Coma scale<5), respiratory distress, jaundice, severe anaemia (Hemocue Hb< 5g/dL),
acidosis (Blood lactate 5 mmol/L), hypoglycaemia (blood glucose< 2.5mmol/L). Cases were
defined as having had cerebral malaria if their Blantyre coma score was less than or equal to 3 on
presentation or early during admission. Participants with co-existing severe or chronic medical
conditions (e.g. bacterial pneumonia, kwashiorkor) unrelated to a severe malarial infection were
excluded. All cases were confirmed as having P. falciparummalaria parasites. Parasite infection
was initially assessed by rapid diagnostic test (HRP-2—Parascreen Pan/Pf) and confirmed by
double read Geimsa-stained thick blood films. Residence and ethnic group of both parents was
recorded from information provided by the caregiver for each child [17].
Controls (n = 477) were recruited matched on ward of residence, ethnicity and age using
household lists during a four-week period in August 2008. Study participants resided in 33 geo-
graphical wards (including Mtindiro 9.6%, Kwafungo 8.5%, Mkata 6.3%, Kwedizinga 6.0%,
others each< 5.0%) surrounding Muheza town in the Tanga region. The participants had a
median age of*2.6 years, and were predominantly from seven ethnic groups (see Table 1). Be-
cause of limited sample size, we did not perform a detailed analysis based on different ethnic
groups or wards of residence.
To complement the case-control collection, we collected samples anonymously from 60
healthy parental and child trios (120 parents, 60 children) during 2007 and 2008 from lowland
villages near the West Usambara mountains in the Tanga region of Tanzania, which ranges
from high to medium levels of malaria transmission. No malaria phenotypic data is available
on these individuals, but their genotypic profiles were used to provide validation data of the ge-
netic aspects of the case-control study.
Sample collection and preparation
Approximately 3ml of venous blood was collected from participants into EDTA vacutainers. A
blood film was prepared and haemoglobin levels measured by hemocue. Children in the con-
trol group with haemoglobin levels of<11g/DL were referred to the nearest health facility;
those with a positive blood film were treated in line with Tanzanian national treatment guide-
lines and excluded from the genetic analysis. Samples were spun at 5000rpm for 5 minutes and
the plasma removed and stored for future analysis. DNA was extracted and purified from the
blood cell pellet using a nucleon kit (see [17] for details).
African G6PD Alleles and Severe Malaria in Tanzania
PLOS Genetics | DOI:10.1371/journal.pgen.1004960 February 11, 2015 10 / 14
Sample genotyping
Genomic DNA samples were genotyped on a SequenomMassArray genotyping platform
[17,33]. The iPlex genotyping assays included 68 G6PD single nucleotide polymorphism (SNP)
positions (identified through resequencing and the 1000 genomes project, described in [9, 32]),
HbS (rs334), HbC (rs33930165), HbE (rs33950507), and two SNPs that allow an estimate of
the ABO blood group rs8176719, rs8176746). In particular, the rs8176719 derived allele results
in a non-functional enzyme, and group O individuals are DD, while non-O Individuals are ei-
ther II or ID. In addition, rs8176746 is involved in the enzyme's substrate selection and there-
fore defines either the A or B blood groups. A full list of SNPs can be found in S1 Table. The
α3.7-thalssaemia deletion was typed separately by PCR [17].
Statistical analysis
All analyses involving SNPs were stratified by gender. Genotypic deviations fromHardy-Wein-
berg equilibrium (HWE) in females were assessed using a Chi-square statistical test. SNPs
were excluded from analysis if they had at least 10% of genotype calls missing, more than 2%
of males genotype calls were (falsely) called heterozygous, or if there was a distortion from
HWE in female controls (HWE Chi-square P<0.00001) [9]. On this basis, 6 SNPs were exclud-
ed (rs766419, rs743545, rs743548, b36_153424319, rs2472393, b36_153426354). A further 33
SNPs with minor allele frequency less than 1% were also removed, leaving 29 high quality SNPs
for association analysis (listed in S2 Table). The 29 SNPs are located in a genomic region with
known regulatory capacity (transcription factor binding and DNase peaks (regulomedb.org),
and both promoter and enhancer histone marks, with a number of different binding proteins
and regulatory motif changes (compbio.mit.edu/HaploReg)).
Case-control association analysis using SNP alleles or genotypes was undertaken within a
logistic regression framework, and included age and ethnic group as covariates. In this ap-
proach we modelled the SNP of interest assuming several related genotypic mechanisms (addi-
tive, dominant, recessive, heterozygous advantage and general models) and reported the
minimum p-value from these correlated tests. Epistatic effects between polymorphisms were
considered by inclusion of statistical interactions in these models. The haplotypes of females
were inferred from genotypes using an expectation-maximization algorithm [34]. Haplotype
association testing was performed using the regression models [34]. Linkage disequilibrium
was estimated using the pairwise D-prime (and R-square) metrics [35]. Performing multiple
statistical tests leads to inflation in the occurrence of false positives. A Bonferroni correction
would be too conservative because all SNPs are from the same gene. A permutation approach
that accounted for the correlation between tests estimated that a p-value cut-off of 0.006 would
ensure a global significance level of 5%. All analyses were performed using the R statistical soft-
ware. The R haplo.stat library was used to implement haplotype analysis. The Tajima’s Dmet-
ric was used to quantify evidence of balancing selection based on the allele frequency spectrum
[36]. A negative Tajima's D indicates purifying selection and/or population size expansion,
while positive values may indicate balancing selection. Values greater than +2 or less than -2
are likely to be significant [36].
Ethics
All DNA samples were collected and genotyped following signed and informed written
consent from a parent or guardian. Ethics approval for all procedures was obtained from
both LSHTM (#2087) and the Tanzanian National Institute of Medical Research (NIMR/
HQ/R.8a/Vol.IX/392).
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232-T, b36_153426313-G, b36_153427466-T, rs5986992-C, b36_153429686-G, rs5986997-C
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